NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

Oct. 22 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-21	€0.8860	+3.02%	26,673
26-08-20	€0.8600	-0.92%	32,827
26-08-19	€0.8680	-0.23%	8,189
26-08-18	€0.8700	0.00%	3,313
26-08-17	€0.8700	+4.57%	24,822

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris 11:55:00 2026-08-21 am EDT			5-day change	1st Jan Change
0.8860 ^EUR	+3.02%		+6.49%	-24.79%

Jul. 28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
Jul. 07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI

Market Cap	11.23M 13.11M 10.51M 9.61M 18.08M 1.25B 18.29M 124M 48.35M 630M 49.22M 48.14M 2.08B	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	9.61M 11.22M 8.99M 8.22M 15.48M 1.07B 15.65M 106M 41.38M 539M 42.12M 41.2M 1.78B	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

Jul. 28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
Jul. 07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
Jun. 30	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
Jun. 30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
Jun. 01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
Jun. 01	NFL Biosciences validates breakthrough in personalized medicine
May. 26	Glimmers of hope for Middle East peace grow brighter
May. 26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
May. 25	NFL Biosciences files new patent application
May. 25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
May. 11	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
May. 04	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
Apr. 15	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

25-10-20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
24-10-02	NFL Biosciences: Invest Securities reduces its target
24-07-15	NFL Biosciences: Invest Securities raises its target

NFL Biosciences Stock

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news : NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Course Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Jul. 28	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
Jul. 07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
Jun. 30	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
Jun. 01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU
May. 25	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application	BU

Jul. 28	NFL Biosciences dépose la demande d'autorisation de l'étude clinique de phase 2 TONIC évaluant NFL-102 dans le sevrage tabagique
Jul. 07	NFL Biosciences : Bilan semestriel du contrat de liquidité
Jul. 07	Reconnaissance scientifique internationale pour NFL Biosciences : 3 présentations retenues au congrès SRNT-Europe 2026, dont une communication orale sur NFL-102
Jun. 30	NFL Biosciences valide la production industrielle du NFL-102 contre la tabagisme
Jun. 30	NFL Biosciences annonce la fabrication avec succès d’un lot clinique GMP de NFL-102 et valide sa chaîne industrielle de production

1 day	+3.02%
1 week	+6.49%
Current month	+1.84%
1 month	+6.75%
6 months	-20.18%
Current year	-24.79%

1 week	0.83	0.89
1 month	0.82	0.89
Current year	0.8	1.85
1 year	0.8	1.85
3 years	0.8	3.31
5 years	0.55	5
10 years	0.55	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	2024-10-16
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	2023-02-26
Bruno Lafont CHM	Chairman	-	2024-10-16
Francis Ahner BRD	Director/Board Member	-	2021-05-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	+3.02%	+6.49%	-43.85%	-65.53%	13.11M
WUXI APPTEC CO., LTD.	-3.00%	+2.27%	+73.26%	+109.90%	72.12B
ARGENX SE	+1.90%	+23.53%	+59.48%	+94.82%	65.85B
BIONTECH SE	+5.12%	+25.22%	+5.13%	-5.86%	29.28B
INSMED INCORPORATED	+0.55%	+1.64%	-4.63%	+480.92%	27.47B
WUXI BIOLOGICS (CAYMAN) INC.	+2.74%	+12.98%	+54.92%	+25.77%	26.7B
GENMAB A/S	+0.47%	+6.12%	+37.01%	-15.31%	20.06B
PHARMAESSENTIA CORPORATION	+1.82%	-6.67%	+251.36%	+388.91%	18.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.94%	+3.36%	+15.30%	+548.19%	16.4B
EXELIXIS, INC.	+0.73%	+5.54%	+39.99%	+151.77%	13.4B
Average	+1.43%	+8.18%	+48.80%	+171.36%	28.95B
Weighted average by Cap.	+0.74%	+9.48%	+58.02%	+157.85%

	2024	2025
Net sales	46 53.71 43.04 39.37 74.09 5.14K 74.93 508.71 198.09 2.58K 201.65 197.25 8.53K	188 219.51 175.9 160.92 302.81 21.01K 306.25 2.08K 809.6 10.55K 824.15 806.14 34.88K
Net income	-2.08M -2.43M -1.95M -1.78M -3.35M -233M -3.39M -23.01M -8.96M -117M -9.12M -8.92M -386M	-3.32M -3.87M -3.1M -2.84M -5.34M -371M -5.4M -36.69M -14.29M -186M -14.55M -14.23M -616M
Net Debt	-2.07M -2.42M -1.94M -1.77M -3.34M -232M -3.38M -22.92M -8.93M -116M -9.09M -8.89M -385M	-1.62M -1.89M -1.52M -1.39M -2.61M -181M -2.64M -17.91M -6.97M -90.88M -7.1M -6.94M -300M